Tuesday, October 19, 2021

Tag: CoronaVirus Cure

Biotech Benefits from UpListing – $7.00 Target Price from Think Equity

PetVivo Holdings, Inc. (NASDAQ: PETV), is new to the NASDAQ and has historically been a light trader in terms of volume.  September however marked...

Uplisted to NASDAQ Today! Patent Protection and Security in the Healthcare...

Some of the largest healthcare companies in the world include UnitedHealth Group Inc. (NYSE: UNH), Pfizer Inc. (NYSE: PFE), and Abbvie Inc. (NYSE: ABBV). These companies are currently sitting above or close to their all-time-high.

5 Small-Cap Pharma Stocks to Buy in June

While the COVID-19 pandemic has cast doubt on many investments, pharma stocks have never looked better. The need for novel treatments and therapies is...

Celledex gaining traction on experimental Cancer Vaccine while Avalon Globocare paves...

In other ongoing research looking at cancer vaccines, the Cancer Research Institute, in partnership with the Parker Institute for Cancer Immunotherapy, is studying a combination of a vaccine with the adjuvants Flt3 ligand and poly-ICLC plus the checkpoint inhibitor nivolumab (Opdivo) and standard-of-care radiation in castrate-resistant prostate cancer. Results are expected in the next six to 12 months, said Jill O’Donnell-Tormey, chief executive officer and director of scientific affairs at the Cancer Research Institute.

Marble Arch Research Report Healixa, Inc. (OTC Pink: EMOR)

COMPANY SUMMARY On June 22, 2020, Emerald Organic Products Inc. (OTCPK: EMOR), a Nevada Corporation, changed its name to Healixa Inc., to reflect the company’s...

Some Experts worry about Next-Generation COVID-19 Vaccines , while they know...

We may find out whether this is going to be a problem sooner than you’d think. Moderna NASDAQ: MRNA is working with the National Institute of Allergy and Infectious Diseases — which helped it design its original Covid vaccine — to test an updated version of its vaccine that targets the variant first spotted in South Africa, B.1.351. That variant appears to be able to evade immune responses triggered by earlier versions of the virus.

Healthcare Technology Disruptor Obtains National Reach

Look at Healixa, Inc. (OTC Pink: EMOR)

A sub 100 million market cap company teams up wit MIT...

Regarding VX-864, its experimental treatment for the rare, inherited lung disease called alpha-1 antitrypsin deficiency, Vertex said a readout of a Phase 2 study is expected in the first half of the year. Last October, Vertex was forced to shelve its first drug for alpha-1 antitrypsin deficiency due to liver toxicity. Independent study monitors are taking regular looks at the safety data from the ongoing VX-864 study, and to date, patient enrollment continues, Vertex said Monday.

Skeptics grow impatient awaiting Cel-Sci to release there Phase 3 data...

No legitimate reason exists for Cel-Sci to be taking this long, even accounting for Covid. The simple truth is Cel-Sci is trying to bury Multikine’s negative results, as it did previously when independent monitors tried to shut the study down twice, or when the FDA halted the study citing an “unreasonable and significant risk of illness or injury to human subjects.”

Amgen’s KRAS Cancer Drug slumps while a much smaller player makes...

Although the company did a poor job answering questions last week — Why suddenly study a lower dose of sotorasib if the higher dose is fine? Did the FDA discover something bad in sotorasib’s safety profile during its review? — it insisted there was nothing wrong with the 960 mg dose of sotorasib. Amgen also said it was the FDA that proposed looking at the efficacy and safety of a lower dose as a “post-marketing requirement” — meaning, presumably, after the higher dose was already approved.